Oral Nutritional Supplement Preferences in Patients With Cancer

Last updated: November 28, 2023
Sponsor: University of Bergen
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neoplasms

Weight Loss

Diet And Nutrition

Treatment

Taste session of five ONS flavors

Clinical Study ID

NCT05816369
Cancer Taste Study
  • Ages > 18
  • All Genders

Study Summary

Patients diagnosed with cancer have a particularly high risk of developing malnutrition due to the disease itself and due to symptoms of cancer treatments that can affect food intake such as reduced appetite, nausea, fatigue, and alterations in taste and smell. Nutritional treatment is essential in the prevention and treatment of malnutrition. Oral nutritional supplements (ONS) are often recommended to cancer patients who need to increase their nutritional intake and are unable to meet their nutritional requirements by consumption of normal food alone. However, patient compliance with ONS depends on sensory acceptability of such products. Therefore, the objective of this study is to investigate preferences of sensory characteristics of ONS among cancer patients. Additionally, possible associations between taste and smell alterations and dietary intake, malnutrition risk, and quality of life will be investigated. The results from this study will optimize recommendations of ONS in the clinical setting and encourage new efforts among manufacturers in developing acceptable sensory characteristics of ONS to cancer patients. Findings from this study will contribute to improving nutritional treatment for cancer patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Ambulatory patients diagnosed with lung cancer
  • Patients receiving cancer treatment of different types
  • Age 18 years or more
  • Provided signed informed consent
  • Understand written and oral Norwegian

Exclusion

Exclusion Criteria:

  • Severe mental or cognitive disorders
  • Contraindication to consume ONS (dysphagia, inability to swallow oral nutritionalsupplements)
  • Allergic or intolerant to any of the ingredients in the ONS
  • Terminally ill patients (<3 months to live)
  • A clinically significant disease or condition that could, in the investigator'sopinion make the patient unfit for the study

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Taste session of five ONS flavors
Phase:
Study Start date:
April 11, 2023
Estimated Completion Date:
September 30, 2024

Connect with a study center

  • University of Bergen

    Bergen, Vestland 5021
    Norway

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.